JAMA Dermatology

Papers
(The H4-Index of JAMA Dermatology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Error in Author Surname in Byline195
Melanoma Screening138
Can Serum Biomarkers for Prurigo Nodularis Expose Pathophysiology or Just Treatment Response?134
Group Omitted From Article Byline132
Frequency of Skin Biopsies for Psoriasis by Race and Ethnicity106
Exanthematous Eruption in a Patient With Known Chronic Graft-vs-Host Disease and Recent Measles Vaccination101
Assessment of Cutaneous Vasculitis and Quality of Life88
Disordered Eating in Hidradenitis Suppurativa82
Recurrence Rate of Melanoma In Situ Excised With a 5-mm Excisional Margin82
Prevalence of Contact Allergens in Natural Skin Care Products From US Commercial Retailers81
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice76
Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia70
Tofacitinib for Treatment of Acquired Reactive Perforating Collagenosis68
Asymptomatic Irregular Pigmented Lesions of the Vulva68
Treatment With Ataluren for Wound Healing and Health Complications in a Patient With Junctional Epidermolysis Bullosa67
Alopecia Areata67
Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis66
Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records63
Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults62
Parental E-Cigarette Use and Pediatric Atopic Dermatitis62
Skin Cancer Care in US Veterans—Serving Those Who Served61
Outcomes Associated With Combination Shaving and Cryosurgery Treatment in Patients With Keloid Scars61
Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention58
Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab58
SIGLEC-1 Expression in a Cohort of Patients With Lupus Erythematosus Treated With Anifrolumab58
Preventing Hand-Foot Syndrome in Patients With Cancer57
Prevalence and Patient Characteristics of Ectodermal Dysplasias in Denmark56
JAMA Dermatology55
Treatment With Topical Sirolimus for Recurrent Lymphatic Malformation of the External Urethral Meatus55
Cutaneous Angiosarcoma55
Perceptions of US-Based Muslim Patients of Their Dermatology Care54
Biomarkers of Tretinoin Precursors and Tretinoin Efficacy in Patients With Moderate to Severe Facial Photodamage54
Association of Persistent Rubella Virus With Idiopathic Skin Granulomas in Clinically Immunocompetent Adults53
Nicotinamide for Skin Cancer Chemoprevention53
Parvovirus B19 Infection52
Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa52
Human Papillomavirus Diversity in Asian Individuals With Cutaneous Squamous Cell Carcinoma51
Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis50
Smoking Cessation and Risk of Hidradenitis Suppurativa Development49
Subclinical Synovitis Among Patients With Psoriasis Without Musculoskeletal Involvement48
Clinical and Pathological Spectrum of Prurigo Pigmentosa in Central European Individuals48
Ultraprocessed Food Intake and Psoriasis47
COVID-19 as a Risk Factor For Autoimmune Skin Disease46
ALK-Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition—Reply46
Current State of Dermatology Mobile Applications With Artificial Intelligence Features46
JAMA Dermatology45
3.7180728912354